Literature DB >> 1443113

Suppression of central noradrenergic neuronal activity inhibits hyperglycemia.

G A Smythe1, S R Edwards.   

Abstract

Hypothalamic noradrenergic neuronal activity (NNA) and hepatic glucose output are stimulated by stress. The aim of the present investigation was to examine whether the blockade of noradrenergic responses to stress might suppress the associated hyperglycemia. Mass spectrometry was used for analysis of norepinephrine (NE) and its neuronal metabolite 3,4-dihydroxyphenylglycol (DHPG) in rat hypothalamus, and the ratio DHPG/NE was used as an index of NNA. Treatment of rats with 2-deoxy-D-glucose (500 mg/kg ip, -30 min), yohimbine (10 mg/kg ip, -20 min), or neostigmine (2 micrograms icv, -60 min) increased both NNA and serum glucose (P < 0.05). When rats were additionally pretreated with pentobarbital (60 mg/kg ip; -60 min), the NNA responses were blocked (P < 0.01). At the same time the hyperglycemic responses were also inhibited (P < 0.01). In rats that had reduced NNA due to 7 days "gentling," serum glucose levels were also significantly reduced (P < 0.001) compared with naive controls. The data demonstrate that inhibition of central noradrenergic activity is also associated with an inhibition of hyperglycemia, raising the concept that therapies aimed at reducing central NNA may have a role in the management of diseases with excessive hepatic glucose output such as non-insulin-dependent diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1443113     DOI: 10.1152/ajpendo.1992.263.5.E823

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  4 in total

1.  Rate of fall in blood glucose and recurrent hypoglycemia affect glucose dynamics and noradrenergic activation in the ventromedial hypothalamus.

Authors:  Meredith B Barnes; Marcus A Lawson; J Lee Beverly
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-09-28       Impact factor: 3.619

2.  Norepinephrine regulation of ventromedial hypothalamic nucleus metabolic transmitter biomarker and astrocyte enzyme and receptor expression: Impact of 5' AMP-activated protein kinase.

Authors:  Mostafa M H Ibrahim; Hussain N Alhamami; Karen P Briski
Journal:  Brain Res       Date:  2019-01-07       Impact factor: 3.252

3.  Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia.

Authors:  Igor Elman; David Rott; Alan I Green; Daniel D Langleben; Scott E Lukas; David S Goldstein; Alan Breier
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

4.  Modulation of β-adrenergic receptors in the ventromedial hypothalamus influences counterregulatory responses to hypoglycemia.

Authors:  Barbara Szepietowska; Wanling Zhu; Owen Chan; Adam Horblitt; James Dziura; Robert S Sherwin
Journal:  Diabetes       Date:  2011-10-19       Impact factor: 9.461

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.